Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Louisville, Kentucky Clinical Trials

A listing of Louisville, Kentucky clinical trials actively recruiting patient volunteers.

RESULTS

Found (32) clinical trials

Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study)

This is a Phase 1 platform protocol designed to evaluate various targeted agents for the treatment of relapsed/refractory aggressive Non-Hodgkin's lymphoma (NHL). Each study arm will be conducted in a predefined disease subset. All study arms are open label and allocation to each study arm will not be randomized. As ...

Phase

5.13 miles

Learn More »

Safety and Antitumor Activity Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma

This is a Phase 1b, open-label, single-arm combination study with a dose escalation phase (Part 1) followed by a dose expansion phase (Part 2). The study will enroll approximately 60 patients. A standard 3+3 dose escalation design will be used for Part 1. The DLT period will be the 21 ...

Phase

5.13 miles

Learn More »

PF-06821497 Treatment Of Relapsed/Refractory SCLC Castration Resistant Prostate Cancer and Follicular Lymphoma

This is an open label, multi center, Phase 1 dose escalation study of PF 06821497 administered orally as a single agent BID to patients with SCLC, CRPC, DLBCL and FL (Part 1A). For Part 1B (dose escalation monotherapy), PF 06821497 will be administered as monotherapy in patients with FL. For ...

Phase

5.74 miles

Learn More »

AMG 404 in Patients With Advanced Solid Tumors.

To evaluate the safety and tolerability of AMG 404, a monoclonal antibody that binds to PD-1 and inhibits its engagement with ligands, in patients with advanced solid tumors.

Phase

5.74 miles

Learn More »

Chemotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma

Phase II study in which all patients undergoing IRE for the treatment of locally advanced pancreatic carcinoma will receive either FOLFIRINOX or gemcitabine as peri-ablation treatment.

Phase

5.74 miles

Learn More »

PK Study of Single-Dose ZTI-01 in Children (<12 Years of Age)

Based on pre-dose weight on Day -1, subjects weighing within the 3rd to < 97th percentile based on age - will receive a single, weight adjusted dose of ZTI-01 via continuous IV infusion or syringe pump over a 1- hour (+10 min) period. Pediatric subjects participating in this study will ...

Phase

5.74 miles

Learn More »

A Study To Evaluate Escalating Doses of A Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC

By enrolling patients with advanced NSCLC and metastatic TNBC according to the enrollment criteria, this study will evaluate the first-in-patient safety, PK, PD and early signs of efficacy of the vaccine-based immunotherapy regimen.

Phase

5.74 miles

Learn More »

Study Evaluate the PK Profile of Dalbavancin in Infants and Neonates Patients With Known or Suspected Bacterial Infection

The purpose of this study is to evaluate the Pharmacokinetic (PK) profile of a single intravenous (IV) infusion dose of dalbavancin, and to evaluate the safety and tolerability of a single dalbavancin IV infusion.

Phase

5.74 miles

Learn More »

Phase 1 Trial of Interleukin 12 Gene Therapy for Locally Recurrent Prostate Cancer

The primary purpose of this phase 1 study is to determine the dose-dependent toxicity and maximum tolerated dose (MTD) of oncolytic adenovirus-mediated cytotoxic and IL-12 gene therapy in men with locally recurrent prostate cancer after definitive radiotherapy

Phase

5.74 miles

Learn More »

A Phase 1b/2 Open-Label Study in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer

In the study, a maximum of 48 subjects (18 for the combination with abiraterone/prednisone and 30 for the combination with enzalutamide) will be enrolled initially at a dose of 400 mg tazemetostat twice daily, followed by 600 mg tazemetostat twice daily, followed by 800 mg tazemetostat twice daily, if there ...

Phase

5.74 miles

Learn More »